Radioligand therapy (RLT) used to treat cardiac metastasis of pancreatic neuroendocrine tumor
Key Clinical Message Radioligand Therapy (RLT) in the form of [177Lu] Lu‐DOTA‐TATE (Lutathera®) is a promising treatment for pancreatic neuroendocrine tumors (pNETs) with cardiac metastasis. We present a patient treated with [177Lu] Lu‐DOTA‐TATE that showed shrinkage of metastasis after four treatme...
Main Authors: | Kieran J. Ved, Arjun Bhatt, Aidan M. Burke, Michael C. Larkins, Dishita Pandya, Constantin B. Marcu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-03-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.8622 |
Similar Items
-
Neuroendocrine metastasis to the thyroid from unknown primary and extrathyroidal disease response to peptide receptor radionuclide therapy
by: Tasnim Khessib, MD, et al.
Published: (2023-11-01) -
Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides—Where Are We Now
by: Mitesh Naik, et al.
Published: (2022-02-01) -
Neuroblastoma xenograft models demonstrate the therapeutic potential of 177Lu-octreotate
by: Arman Romiani, et al.
Published: (2021-08-01) -
Lutathera<sup>®</sup> Orphans: State of the Art and Future Application of Radioligand Therapy with <sup>177</sup>Lu-DOTATATE
by: Luca Urso, et al.
Published: (2023-03-01) -
Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy
by: Fiona Ohlendorf, et al.
Published: (2021-03-01)